SLC5A2 and diabetes mellitus: As cardiovascular risk reduction strategies have been established for diabetes, namely sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) [6], undiagnosed diabetes constitutes an important missed opportunity for primary and secondary prevention of diabetes-related complications.